Point of Care Testing Women Health Market
Point-of-Care Testing for Women Health Market Research Report Information by Product (Instruments/Devices, Reagents & Kits, Consumables), by Age (Adolescent, Adult, Geriatric), by Sample Type (Serum, Plasma, Whole Blood, Urine, Others), by Test Type (Testosterone Test, Estradiol Test, Anti-Müllerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-stimulating Hormone Test, Luteinizing Hormone Test, β-hCG Test, Others), by Technology (Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others), by Application (Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections (Chlamydia, Gonorrhea, HIV, Syphilis, Others), Fertility Conditions (Polycystic Ovary Syndrome, Ovulation Disorders, Others), Pregnancy Testing, Others), by Distribution Channel (Offline (Hospital Pharmacies, Retail Pharmacies, Hypermarket/Supermarket) and Online (E-commerce Platforms and Online Pharmacies)), by End User (Hospitals, Diagnostic Laboratories, Home Settings, Others) and Region (North America, Europe, Asia-Pacific, Rest of the World) - Forecast till 2035
Point-of-Care Testing for Women Health Market Overview
The Point-of-Care Testing for Women Health Market was valued at USD 17.69 Billion in 2024. The industry is projected to grow from USD 18.83 Billion in 2025 to USD 33.74 Billion by 2035, exhibi..
